Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. FMS
stocks logo

FMS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
4.74B
-6.77%
0.487
+7.03%
4.94B
+1.17%
0.490
+16.67%
4.94B
+3.01%
0.550
+20.88%
Estimates Revision
The market is revising Downward the revenue expectations for Fresenius Medical Care AG (FMS) for FY2025, with the revenue forecasts being adjusted by -0.01% over the past three months. During the same period, the stock price has changed by -5.65%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.01%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+88.25%
In Past 3 Month
Stock Price
Go Down
down Image
-5.65%
In Past 3 Month
Wall Street analysts forecast FMS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FMS is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast FMS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FMS is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
1 Sell
Moderate Sell
Current: 23.370
sliders
Low
22.00
Averages
22.00
High
22.00
Current: 23.370
sliders
Low
22.00
Averages
22.00
High
22.00
Morgan Stanley
Underweight
downgrade
2025-11-10
Reason
Morgan Stanley
Price Target
2025-11-10
downgrade
Underweight
Reason
Morgan Stanley lowered the firm's price target on Fresenius Medical to EUR 39 from EUR 41 and keeps an Underweight rating on the shares.
BofA
Neutral -> Underperform
downgrade
2025-10-15
Reason
BofA
Price Target
2025-10-15
downgrade
Neutral -> Underperform
Reason
BofA downgraded Fresenius Medical to Underperform from Neutral with a price target of EUR 38, down from EUR 50, citing limited visibility on when patient volumes will recover and margin risks in 2025-26 due to ACA subsidies expiring and a mix shift to value-based care. The firm thinks upcoming potential catalysts are well appreciated and won't drive meaningful near-term upside, the analyst added.
UBS
Neutral -> Sell
downgrade
2025-09-02
Reason
UBS
Price Target
2025-09-02
downgrade
Neutral -> Sell
Reason
UBS downgraded Fresenius Medical to Sell from Neutral with a price target of EUR 38, down from EUR 43.50. The firm says its new analysis shows the company's U.S. dialysis volumes face long-term funnel and mortality challenges. It believes Fresenius Medical's volume misses will be structural.
Morgan Stanley
Robert Davies
Underweight
maintain
2025-08-12
Reason
Morgan Stanley
Robert Davies
Price Target
2025-08-12
maintain
Underweight
Reason
Morgan Stanley analyst Robert Davies raised the firm's price target on Fresenius Medical to EUR 46 from EUR 43 and keeps an Underweight rating on the shares.
Deutsche Bank
Hold
maintain
2025-07-21
Reason
Deutsche Bank
Price Target
2025-07-21
maintain
Hold
Reason
Deutsche Bank raised the firm's price target on Fresenius Medical to EUR 50 from EUR 45 and keeps a Hold rating on the shares.
Goldman Sachs
downgrade
2025-07-01
Reason
Goldman Sachs
Price Target
2025-07-01
downgrade
Reason
Goldman Sachs analysts removed Fresenius Medical Care from the firm's European Conviction List as part of its monthly update.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Fresenius Medical Care AG (FMS.N) is 9.45, compared to its 5-year average forward P/E of 14.08. For a more detailed relative valuation and DCF analysis to assess Fresenius Medical Care AG 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
14.08
Current PE
9.45
Overvalued PE
17.74
Undervalued PE
10.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
7.63
Current EV/EBITDA
6.00
Overvalued EV/EBITDA
8.64
Undervalued EV/EBITDA
6.61

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
0.71
Current PS
0.60
Overvalued PS
0.91
Undervalued PS
0.50
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

FMS News & Events

Events Timeline

(ET)
2025-11-04
07:23:53
Fresenius Medical anticipates low-single-digit revenue growth by 2025.
select
2025-11-04
07:22:57
Fresenius Medical announces Q3 adjusted EPS of EUR 1.10, up from EUR 0.81 a year ago.
select
2025-10-01 (ET)
2025-10-01
09:41:33
Fresenius Medical Names Joseph Turk as CEO of Care Enablement
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-04NASDAQ.COM
Fresenius Medical Care (FMS) Stock Falls Below 200-Day Moving Average
  • 52 Week Range: FMS's stock has a 52-week low of $19.89 and a high of $30.46, with the last trade recorded at $23.65.
  • Market Analysis: The article mentions other dividend stocks that have recently fallen below their 200-day moving average.
  • Author's Perspective: The views expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.
  • Investment Insight: The information provided may be useful for investors tracking stock performance and dividend opportunities.
[object Object]
Preview
9.5
11-04NASDAQ.COM
Fresenius Medical Care Reports Increased Q3 Results and Reaffirms FY25 Forecast

  • Financial Performance: Fresenius Medical Care reported a 29% increase in net income to 275 million euros in Q3, with adjusted net income growing 36% to 322 million euros. Basic earnings per share rose to 0.94 euros from 0.73 euros.

  • Revenue Growth: The company's revenue for the third quarter increased by 3% to 4.89 billion euros, with an 8% rise at constant currency and a 10% organic growth across all operating segments.

  • Future Outlook: Fresenius Medical Care confirmed its fiscal 2025 outlook, expecting positive revenue growth at constant currency in the low-single digits and operating income growth in the high-teens to high-twenties percent range.

  • Cost Savings Program: The company anticipates full-year FME25+ savings to reach 1.05 billion euros by the end of 2027, with associated program costs estimated between 1 billion euros and 1.05 billion euros during the same period.

[object Object]
Preview
3.0
10-25NASDAQ.COM
Reasons to Keep Fresenius Medical Stock in Your Portfolio for the Time Being

  • Growth Potential: Fresenius Medical Care AG & Co. is positioned for growth through strategic acquisitions and partnerships, with a market cap of $15.8 billion and an expected earnings growth of 19.3% over the next five years.

  • Strong Global Presence: The company has a robust global footprint, operating 3,624 clinics and serving over 308,000 patients, while expanding its services in various regions despite challenges from the pandemic and divestitures.

  • Financial Performance: FMS reported strong Q2 results, exceeding earnings and revenue estimates, and confirmed its target for significant annual savings through its transformation program, despite facing rising labor and inflation costs.

  • Market Challenges: The company is dealing with increased labor expenses and treatment volume declines due to divestitures, which have impacted its short-term prospects, although revenue estimates for 2025 indicate potential growth.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Fresenius Medical Care AG (FMS) stock price today?

The current price of FMS is 23.37 USD — it has decreased -0.85 % in the last trading day.

arrow icon

What is Fresenius Medical Care AG (FMS)'s business?

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. It has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. It develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. It owns, operates, or manages dialysis clinics sells products to other dialysis providers.

arrow icon

What is the price predicton of FMS Stock?

Wall Street analysts forecast FMS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FMS is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Fresenius Medical Care AG (FMS)'s revenue for the last quarter?

Fresenius Medical Care AG revenue for the last quarter amounts to 5.71B USD, increased 9.17 % YoY.

arrow icon

What is Fresenius Medical Care AG (FMS)'s earnings per share (EPS) for the last quarter?

Fresenius Medical Care AG. EPS for the last quarter amounts to 1.10 USD, increased 37.50 % YoY.

arrow icon

What changes have occurred in the market's expectations for Fresenius Medical Care AG (FMS)'s fundamentals?

The market is revising Downward the revenue expectations for Fresenius Medical Care AG (FMS) for FY2025, with the revenue forecasts being adjusted by -0.01% over the past three months. During the same period, the stock price has changed by -5.65%.
arrow icon

How many employees does Fresenius Medical Care AG (FMS). have?

Fresenius Medical Care AG (FMS) has 111513 emplpoyees as of December 05 2025.

arrow icon

What is Fresenius Medical Care AG (FMS) market cap?

Today FMS has the market capitalization of 13.55B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free